{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:54:42Z","timestamp":1788400482757,"version":"build-2803163510"},"reference-count":120,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2016.0477","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:27:14Z","timestamp":1525253234000},"source":"Crossref","is-referenced-by-count":35,"title":["The Indications, Applications, and Risks of Proton Pump Inhibitors"],"prefix":"10.3238","author":[{"given":"Joachim","family":"M\u00f6ssner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"10.3238\/arztebl.2016.0477_ref1","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner J: Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungsreport 2015. Berlin, Heidelberg, New York: Springer 2015; chapter 30: 757\u20138","DOI":"10.1007\/978-3-662-47186-9_30"},{"key":"10.3238\/arztebl.2016.0477_ref2","doi-asserted-by":"crossref","unstructured":"Edwards SJ, Lind T, Lundell L, Das R: Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis\u2014a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547\u201356","DOI":"10.1111\/j.1365-2036.2009.04077.x"},{"key":"10.3238\/arztebl.2016.0477_ref3","doi-asserted-by":"crossref","unstructured":"Koop H, Fuchs KH, Labenz J, et al.: Mitarbeiter der Leitliniengruppe: S2k-Leitlinie. Gastro\u00f6sophageale Refluxkrankheit unter Federf\u00fchrung der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) AWMF Register Nr. 021\u2013013 Z. Gastroenterol 2014; 52: 1299\u2013346","DOI":"10.1055\/s-0034-1385202"},{"key":"10.3238\/arztebl.2016.0477_ref4","doi-asserted-by":"crossref","unstructured":"Lau JY, Leung WK, Wu JC, et al.: Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007; 356: 1631\u201340","DOI":"10.1056\/NEJMoa065703"},{"key":"10.3238\/arztebl.2016.0477_ref5","doi-asserted-by":"crossref","unstructured":"Sung JJ, Barkun A, Kuipers EJ, et al.; Peptic Ulcer Bleed Study Group: Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009; 150: 455\u201364","DOI":"10.7326\/0003-4819-150-7-200904070-00105"},{"key":"10.3238\/arztebl.2016.0477_ref6","doi-asserted-by":"crossref","unstructured":"Chen CC, Lee JY, Fang YJ, et al.: Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. Aliment Pharmacol Ther 2012; 35: 894\u2013903","DOI":"10.1111\/j.1365-2036.2012.05047.x"},{"key":"10.3238\/arztebl.2016.0477_ref7","doi-asserted-by":"crossref","unstructured":"Mo C, Sun G, Lu ML, et al.: Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21: 5382\u201392","DOI":"10.3748\/wjg.v21.i17.5382"},{"key":"10.3238\/arztebl.2016.0477_ref8","doi-asserted-by":"crossref","unstructured":"Zullo A, De Francesco V, Hassan C, Morini S, Vaira D: The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353\u20137","DOI":"10.1136\/gut.2007.125658"},{"key":"10.3238\/arztebl.2016.0477_ref9","doi-asserted-by":"crossref","unstructured":"Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F: Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553\u201362","DOI":"10.7326\/0003-4819-147-8-200710160-00008"},{"key":"10.3238\/arztebl.2016.0477_ref10","doi-asserted-by":"crossref","unstructured":"Miehlke S, Schneider-Brachert W, Kirsch C, et al.: One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008; 13: 69\u201374","DOI":"10.1111\/j.1523-5378.2007.00588.x"},{"key":"10.3238\/arztebl.2016.0477_ref11","doi-asserted-by":"crossref","unstructured":"Fischbach W, Malfertheiner P, Hoffmann JC, et al.: German society for hygiene and microbiology; German society for pediatric gastroenterology and nutrition e. V; German society for rheumatology. S3-Leitlinie \u201eHelicobacter pylori und gastroduodenale Ulkuskrankheit.\u201d Z Gastroenterol 2009; 47: 68\u2013102","DOI":"10.1055\/s-0028-1109062"},{"key":"10.3238\/arztebl.2016.0477_ref12","doi-asserted-by":"crossref","unstructured":"Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Kist M, Koletzko S; Association of Scientific Medical Societies: Helicobacter pylori and gastroduodenal ulcer disease. Dtsch Arztebl Int 2009; 106: 801\u20138","DOI":"10.3238\/arztebl.2009.0801"},{"key":"10.3238\/arztebl.2016.0477_ref13","doi-asserted-by":"crossref","unstructured":"Miehlke S, Krasz S, Schneider-Brachert W, et al.: Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011; 16: 420\u20136","DOI":"10.1111\/j.1523-5378.2011.00867.x"},{"key":"10.3238\/arztebl.2016.0477_ref14","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Bazzoli F, Delchier JC, et al.; Pylera Study Group: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905\u201313","DOI":"10.1016\/S0140-6736(11)60020-2"},{"key":"10.3238\/arztebl.2016.0477_ref15","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, et al.; European Helicobacter Study Group: Management of Helicobacter pylori infection\u2014 the Maastricht IV\/ Florence Consensus Report. Gut\u00a02012; 61: 646\u201364","DOI":"10.1136\/gutjnl-2012-302084"},{"key":"10.3238\/arztebl.2016.0477_ref16","doi-asserted-by":"crossref","unstructured":"Gatta L, Vakil N, Vaira D, Scarpignato C: Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587. doi: 10.1136\/bmj.f4587","DOI":"10.1136\/bmj.f4587"},{"key":"10.3238\/arztebl.2016.0477_ref17","unstructured":"Yuan Y, Ford AC, Khan KJ, et al.: Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013 Dec 11; 12: CD008337. doi: 0.1002\/14651858.CD008337.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref18","doi-asserted-by":"crossref","unstructured":"Mandorfer M, Bota S, Schwabl P, et al.: Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One 2014; 9: e110503","DOI":"10.1371\/journal.pone.0110503"},{"key":"10.3238\/arztebl.2016.0477_ref19","doi-asserted-by":"crossref","unstructured":"Lo EA, Wilby KJ, Ensom MH: Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother 2015; 49: 207\u201319","DOI":"10.1177\/1060028014559244"},{"key":"10.3238\/arztebl.2016.0477_ref20","doi-asserted-by":"crossref","unstructured":"Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR: Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648\u201354","DOI":"10.1111\/j.1572-0241.2007.01509.x"},{"key":"10.3238\/arztebl.2016.0477_ref21","doi-asserted-by":"crossref","unstructured":"Reimer C, S\u00f8ndergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80\u20137","DOI":"10.1053\/j.gastro.2009.03.058"},{"key":"10.3238\/arztebl.2016.0477_ref22","doi-asserted-by":"crossref","unstructured":"Kuipers EJ, Sung JJ, Barkun A, et al.: Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther 2011; 28: 150\u20139","DOI":"10.1007\/s12325-010-0095-5"},{"key":"10.3238\/arztebl.2016.0477_ref23","doi-asserted-by":"crossref","unstructured":"Lam JR, Schneider JL, Zhao W, Corley DA: Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310: 2435\u201342","DOI":"10.1001\/jama.2013.280490"},{"key":"10.3238\/arztebl.2016.0477_ref24","doi-asserted-by":"crossref","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C: Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93\u2013101","DOI":"10.1053\/j.gastro.2010.03.055"},{"key":"10.3238\/arztebl.2016.0477_ref25","doi-asserted-by":"crossref","unstructured":"Eom CS, Park SM, Myung SK, Yun JM, Ahn JS: Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011; 9: 257\u201367","DOI":"10.1370\/afm.1243"},{"key":"10.3238\/arztebl.2016.0477_ref26","doi-asserted-by":"crossref","unstructured":"Kwok CS, Yeong JK, Loke YK: Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011; 48: 768\u201376","DOI":"10.1016\/j.bone.2010.12.015"},{"key":"10.3238\/arztebl.2016.0477_ref27","doi-asserted-by":"crossref","unstructured":"Yu EW, Bauer SR, Bain PA, Bauer DC: Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124: 519\u201326","DOI":"10.1016\/j.amjmed.2011.01.007"},{"key":"10.3238\/arztebl.2016.0477_ref28","doi-asserted-by":"crossref","unstructured":"Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K: Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209\u201318","DOI":"10.1038\/ajg.2011.113"},{"key":"10.3238\/arztebl.2016.0477_ref29","doi-asserted-by":"crossref","unstructured":"Johnstone J, Nerenberg K, Loeb M: Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165\u201377","DOI":"10.1111\/j.1365-2036.2010.04284.x"},{"key":"10.3238\/arztebl.2016.0477_ref30","doi-asserted-by":"crossref","unstructured":"Giuliano C, Wilhelm SM, Kale-Pradhan PB: Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337\u201344","DOI":"10.1586\/ecp.12.20"},{"key":"10.3238\/arztebl.2016.0477_ref31","doi-asserted-by":"crossref","unstructured":"Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS: Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310\u20139","DOI":"10.1503\/cmaj.092129"},{"key":"10.3238\/arztebl.2016.0477_ref32","doi-asserted-by":"crossref","unstructured":"Filion KB, Chateau D, Targownik LE, et al.; CNODES Investigators: Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63: 552\u20138","DOI":"10.1136\/gutjnl-2013-304738"},{"key":"10.3238\/arztebl.2016.0477_ref33","doi-asserted-by":"crossref","unstructured":"Trikudanathan G, Israel J, Cappa J, O'Sullivan DM: Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients\u2014a systematic review and meta-analysis. Int J Clin Pract 2011; 65: 674\u20138","DOI":"10.1111\/j.1742-1241.2011.02650.x"},{"key":"10.3238\/arztebl.2016.0477_ref34","doi-asserted-by":"crossref","unstructured":"Deshpande A, Pasupuleti V, Thota P, et al.: Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 235\u201342","DOI":"10.1111\/jgh.12065"},{"key":"10.3238\/arztebl.2016.0477_ref35","doi-asserted-by":"crossref","unstructured":"Deshpande A, Pant C, Pasupuleti V, et al.: Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 225\u201333","DOI":"10.1016\/j.cgh.2011.09.030"},{"key":"10.3238\/arztebl.2016.0477_ref36","doi-asserted-by":"crossref","unstructured":"Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK: Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011\u20139","DOI":"10.1038\/ajg.2012.108"},{"key":"10.3238\/arztebl.2016.0477_ref37","doi-asserted-by":"crossref","unstructured":"Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al.: Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012; 7: e50836","DOI":"10.1371\/journal.pone.0050836"},{"key":"10.3238\/arztebl.2016.0477_ref38","doi-asserted-by":"crossref","unstructured":"Ho PM, Maddox TM, Wang L, et al.: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937\u201344","DOI":"10.1001\/jama.2009.261"},{"key":"10.3238\/arztebl.2016.0477_ref39","doi-asserted-by":"crossref","unstructured":"Kwok CS, Nijjar RS, Loke YK: Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf 2011; 34: 47\u201357","DOI":"10.2165\/11584750-000000000-00000"},{"key":"10.3238\/arztebl.2016.0477_ref40","doi-asserted-by":"crossref","unstructured":"Depta JP, Bhatt D:. Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 2012; 27: 642\u201350","DOI":"10.1097\/HCO.0b013e32835830b6"},{"key":"10.3238\/arztebl.2016.0477_ref41","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner J, Caca K: Developments in the inhibition of gastric acid secretion. Eur J Clin Invest 2005; 35: 469\u201375","DOI":"10.1111\/j.1365-2362.2005.01543.x"},{"key":"10.3238\/arztebl.2016.0477_ref42","doi-asserted-by":"crossref","unstructured":"Miner P, Katz PO, Chen Y, Sostek M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616\u201320","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"10.3238\/arztebl.2016.0477_ref43","doi-asserted-by":"crossref","unstructured":"Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ: Symptomatic reflux disease: the present, the past and the future. Gut 2014; 63: 1185\u201393","DOI":"10.1136\/gutjnl-2013-306393"},{"key":"10.3238\/arztebl.2016.0477_ref44","doi-asserted-by":"crossref","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J: Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871\u201380","DOI":"10.1136\/gutjnl-2012-304269"},{"key":"10.3238\/arztebl.2016.0477_ref45","doi-asserted-by":"crossref","unstructured":"Spechler SJ, Souza RF: Barrett's esophagus. N Engl J Med 2014; 371: 836\u201345","DOI":"10.1056\/NEJMra1314704"},{"key":"10.3238\/arztebl.2016.0477_ref46","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; (4): CD001960. Update in Cochrane Database Syst Rev 2011; (2): CD001960. Update of Cochrane Database Syst Rev 2004; (4): CD001960.","DOI":"10.1002\/14651858.CD001960.pub4"},{"key":"10.3238\/arztebl.2016.0477_ref47","unstructured":"North of England Dyspepsia Guideline Development Group (UK): Evidence-Based Clinical Practice Guideline: Dyspepsia: Managing dyspepsia in adults in primary care. Newcastle upon Tyne (UK): University of Newcastle upon Tyne; 2004."},{"key":"10.3238\/arztebl.2016.0477_ref48","doi-asserted-by":"crossref","unstructured":"Talley NJ, Lauritsen K: The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50 Suppl 4: iv36\u201341","DOI":"10.1136\/gut.50.suppl_4.iv36"},{"key":"10.3238\/arztebl.2016.0477_ref49","doi-asserted-by":"crossref","unstructured":"Andersson T, R\u00f6hss K, Bredberg E, Hassan-Alin M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563\u20139","DOI":"10.1046\/j.1365-2036.2001.01087.x"},{"key":"10.3238\/arztebl.2016.0477_ref50","doi-asserted-by":"crossref","unstructured":"Stedman CA, Barclay ML: Review article; comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963\u201378","DOI":"10.1046\/j.1365-2036.2000.00788.x"},{"key":"10.3238\/arztebl.2016.0477_ref51","doi-asserted-by":"crossref","unstructured":"Labenz J, Armstrong D, Lauritsen K et al.; Expo Study Investigators: A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739\u201346","DOI":"10.1111\/j.1365-2036.2005.02368.x"},{"key":"10.3238\/arztebl.2016.0477_ref52","doi-asserted-by":"crossref","unstructured":"Labenz J, Armstrong D, Lauritsen K: Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803\u201311","DOI":"10.1111\/j.1365-2036.2005.02643.x"},{"key":"10.3238\/arztebl.2016.0477_ref53","doi-asserted-by":"crossref","unstructured":"Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A: Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis\u2014results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther 2009; 29: 1165\u201371","DOI":"10.1111\/j.1365-2036.2009.03990.x"},{"key":"10.3238\/arztebl.2016.0477_ref54","doi-asserted-by":"crossref","unstructured":"Gillessen A, Beil W, Modlin IM, Gatz G, Hole U: 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38: 332\u201340","DOI":"10.1097\/00004836-200404000-00007"},{"key":"10.3238\/arztebl.2016.0477_ref55","doi-asserted-by":"crossref","unstructured":"Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM: Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006; 4: 1452\u20138","DOI":"10.1016\/j.cgh.2006.09.013"},{"key":"10.3238\/arztebl.2016.0477_ref56","doi-asserted-by":"crossref","unstructured":"Wedemeyer RS, Blume H: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37: 201\u201311","DOI":"10.1007\/s40264-014-0144-0"},{"key":"10.3238\/arztebl.2016.0477_ref57","doi-asserted-by":"crossref","unstructured":"Klinkenberg-Knol EC, Jansen JM, Festen HP, Meuwissen SG, Lamers CB: Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; 1: 349\u201351","DOI":"10.1016\/S0140-6736(87)91726-0"},{"key":"10.3238\/arztebl.2016.0477_ref58","doi-asserted-by":"crossref","unstructured":"Bate CM, Keeling PW, O'Morain C, et al.: Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990; 31: 968\u201372","DOI":"10.1136\/gut.31.9.968"},{"key":"10.3238\/arztebl.2016.0477_ref59","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner J, H\u00f6lscher AH, Herz R, Schneider A: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321\u20136","DOI":"10.1111\/j.1365-2036.1995.tb00388.x"},{"key":"10.3238\/arztebl.2016.0477_ref60","doi-asserted-by":"crossref","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798\u20131810","DOI":"10.1053\/gast.1997.v112.pm9178669"},{"key":"10.3238\/arztebl.2016.0477_ref61","doi-asserted-by":"crossref","unstructured":"Sharma VK, Leontiadis GI, Howden CW: Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 227\u201331","DOI":"10.1046\/j.1365-2036.2001.00904.x"},{"key":"10.3238\/arztebl.2016.0477_ref62","doi-asserted-by":"crossref","unstructured":"Klok RM, Postma MJ, van Hout BA, Brouwers JR: Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003; 17: 1237\u201345","DOI":"10.1046\/j.1365-2036.2003.01562.x"},{"key":"10.3238\/arztebl.2016.0477_ref63","doi-asserted-by":"crossref","unstructured":"Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18: 587\u201394","DOI":"10.1046\/j.1365-2036.2003.01745.x"},{"key":"10.3238\/arztebl.2016.0477_ref64","doi-asserted-by":"crossref","unstructured":"Vakil N, Fennerty MB: Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559\u201368","DOI":"10.1046\/j.1365-2036.2003.01756.x"},{"key":"10.3238\/arztebl.2016.0477_ref65","doi-asserted-by":"crossref","unstructured":"van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; (4): CD002095","DOI":"10.1002\/14651858.CD002095.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref66","doi-asserted-by":"crossref","unstructured":"DeVault KR, Castell DO; American College of Gastroenterology: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterology 2005; 100: 190\u2013200","DOI":"10.1111\/j.1572-0241.2005.41217.x"},{"key":"10.3238\/arztebl.2016.0477_ref67","doi-asserted-by":"crossref","unstructured":"Edwards SJ, Lind T, Lundell L: Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis\u2014a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24: 743\u201350","DOI":"10.1111\/j.1365-2036.2006.03074.x"},{"key":"10.3238\/arztebl.2016.0477_ref68","doi-asserted-by":"crossref","unstructured":"Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095. Update of Cochrane Database Syst Rev 2010; (11): CD002095.","DOI":"10.1002\/14651858.CD002095.pub4"},{"key":"10.3238\/arztebl.2016.0477_ref69","unstructured":"Khan M, Santana J, Donnellan C, Preston C, Moayyedi P: Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244. Update in Cochrane Database Syst Rev 2011; (2): CD003244."},{"key":"10.3238\/arztebl.2016.0477_ref70","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner J, Koop H, Porst H, W\u00fcbbolding H, Schneider A, Maier C: One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 1087\u201392","DOI":"10.1046\/j.1365-2036.1997.00242.x"},{"key":"10.3238\/arztebl.2016.0477_ref71","doi-asserted-by":"crossref","unstructured":"Bour B, Staub JL, Chousterman M, et al.: Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 2005; 21: 805\u201312","DOI":"10.1111\/j.1365-2036.2005.02413.x"},{"key":"10.3238\/arztebl.2016.0477_ref72","doi-asserted-by":"crossref","unstructured":"Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; (2): CD003245","DOI":"10.1002\/14651858.CD003245.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref73","doi-asserted-by":"crossref","unstructured":"Sj\u00f6stedt S, Befrits R, Sylvan A, et al.: Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 183\u201391","DOI":"10.1111\/j.1365-2036.2005.02553.x"},{"key":"10.3238\/arztebl.2016.0477_ref74","unstructured":"Poynard T, Lemaire M, Agostini H: Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661\u20135"},{"key":"10.3238\/arztebl.2016.0477_ref75","doi-asserted-by":"crossref","unstructured":"Sakaguchi M, Ashida K, Umegaki E, Miyoshi H, Katsu K: Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol 1995; 20 Suppl 2: S27\u201331","DOI":"10.1097\/00004836-199506002-00008"},{"key":"10.3238\/arztebl.2016.0477_ref76","doi-asserted-by":"crossref","unstructured":"Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F, Vigneri S: Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials. Dig Dis Sci 1996; 41: 1108\u201331","DOI":"10.1007\/BF02088227"},{"key":"10.3238\/arztebl.2016.0477_ref77","doi-asserted-by":"crossref","unstructured":"Tunis SR, Sheinhait IA, Schmid CH, Bishop DJ, Ross SD: Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clin Ther 1997; 19: 743\u201357","DOI":"10.1016\/S0149-2918(97)80098-7"},{"key":"10.3238\/arztebl.2016.0477_ref78","doi-asserted-by":"crossref","unstructured":"Hawkey CJ, Karrasch JA, Szczepa\u00f1ski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727\u201334","DOI":"10.1056\/NEJM199803123381105"},{"key":"10.3238\/arztebl.2016.0477_ref79","doi-asserted-by":"crossref","unstructured":"Salas M, Ward A, Caro J: Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2002; 2: 17","DOI":"10.1186\/1471-230X-2-17"},{"key":"10.3238\/arztebl.2016.0477_ref80","doi-asserted-by":"crossref","unstructured":"Lau JY, Sung JJ, Lee KK, et al.: Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310\u20136","DOI":"10.1056\/NEJM200008033430501"},{"key":"10.3238\/arztebl.2016.0477_ref81","doi-asserted-by":"crossref","unstructured":"Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104\u201310","DOI":"10.1056\/NEJMoa021907"},{"key":"10.3238\/arztebl.2016.0477_ref82","doi-asserted-by":"crossref","unstructured":"Chan FK, Ching JY, Hung LC, et al.: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238\u201344","DOI":"10.1056\/NEJMoa042087"},{"key":"10.3238\/arztebl.2016.0477_ref83","doi-asserted-by":"crossref","unstructured":"Chan FK, Wong VW, Suen BY, et al.: Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621\u20136","DOI":"10.1016\/S0140-6736(07)60749-1"},{"key":"10.3238\/arztebl.2016.0477_ref84","unstructured":"Rostom A, Dube C, Wells G, et al.: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; (4): CD002296. Update of Cochrane Database Syst Rev 2000; (4): CD002296."},{"key":"10.3238\/arztebl.2016.0477_ref85","doi-asserted-by":"crossref","unstructured":"Leandro G, Pilotto A, Franceschi M, et al.: Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924\u201336","DOI":"10.1023\/A:1010687115298"},{"key":"10.3238\/arztebl.2016.0477_ref86","doi-asserted-by":"crossref","unstructured":"Labenz J, Blum AL, Bolten WW, et al.: Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329\u201335","DOI":"10.1136\/gut.51.3.329"},{"key":"10.3238\/arztebl.2016.0477_ref87","doi-asserted-by":"crossref","unstructured":"van Zanten SV, Armstrong D, Chiba N, et al.: Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled \u201eENTER\u201d trial. Am J Gastroenterol 2006; 101: 2096\u2013106. Erratum in: Am J Gastroenterol 101: 2171.","DOI":"10.1111\/j.1572-0241.2006.00751.x"},{"key":"10.3238\/arztebl.2016.0477_ref88","doi-asserted-by":"crossref","unstructured":"Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J: Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007; 52: 983\u20137","DOI":"10.1007\/s10620-006-9156-7"},{"key":"10.3238\/arztebl.2016.0477_ref89","doi-asserted-by":"crossref","unstructured":"Vinayek R, Amantea MA, Maton PN, Frucht H, Gardner JD, Jensen RT: Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 1991; 101: 138\u201347","DOI":"10.1016\/0016-5085(91)90470-6"},{"key":"10.3238\/arztebl.2016.0477_ref90","doi-asserted-by":"crossref","unstructured":"Lew EA, Pisegna JR, Starr JA, et al.: Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118: 696\u2013704","DOI":"10.1016\/S0016-5085(00)70139-9"},{"key":"10.3238\/arztebl.2016.0477_ref91","doi-asserted-by":"crossref","unstructured":"Metz DC, Comer GM, Soffer E, et al.: Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006; 23: 437\u201344","DOI":"10.1111\/j.1365-2036.2006.02762.x"},{"key":"10.3238\/arztebl.2016.0477_ref92","doi-asserted-by":"crossref","unstructured":"Metz DC, Soffer E, Forsmark CE, et al.: Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol 2003; 98: 301\u20137","DOI":"10.1111\/j.1572-0241.2003.07262.x"},{"key":"10.3238\/arztebl.2016.0477_ref93","doi-asserted-by":"crossref","unstructured":"Donnellan C, Preston C, Moayyedi P, Sharma N: WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2010; (2): CD003245. Update of Cochrane Database Syst Rev 2005; (2): CD003245.","DOI":"10.1002\/14651858.CD003245.pub3"},{"key":"10.3238\/arztebl.2016.0477_ref94","doi-asserted-by":"crossref","unstructured":"Garg SK, Gurusamy KS: Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2015; 11: CD003243. Update of Cochrane Database Syst Rev 2010; (3): CD003243.","DOI":"10.1002\/14651858.CD003243.pub3"},{"key":"10.3238\/arztebl.2016.0477_ref95","doi-asserted-by":"crossref","unstructured":"Phupong V, Hanprasertpong T: Interventions for heartburn in pregnancy. Cochrane Database Syst Rev 2015; 9: CD011379","DOI":"10.1002\/14651858.CD011379.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref96","doi-asserted-by":"crossref","unstructured":"Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM: Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev 2014; 11: CD008550","DOI":"10.1002\/14651858.CD008550.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref97","doi-asserted-by":"crossref","unstructured":"Gibson PG, Henry RL, Coughlan JL: Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003; (2): CD001496. Update of Cochrane Database Syst Rev 2000; (2): CD001496.","DOI":"10.1002\/14651858.CD001496"},{"key":"10.3238\/arztebl.2016.0477_ref98","doi-asserted-by":"crossref","unstructured":"Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; (1): CD004823. Update of Cochrane Database Syst Rev 2006; (4): CD004823.","DOI":"10.1002\/14651858.CD004823.pub4"},{"key":"10.3238\/arztebl.2016.0477_ref99","doi-asserted-by":"crossref","unstructured":"Sreedharan A, Martin J, Leontiadis GI, et al.: Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; (7): CD005415. Update of Cochrane Database Syst Rev 2006; (4): CD005415.","DOI":"10.1002\/14651858.CD005415.pub3"},{"key":"10.3238\/arztebl.2016.0477_ref100","doi-asserted-by":"crossref","unstructured":"Leontiadis GI, Sharma VK, Howden CW: WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2010; (5): CD002094. Update of Cochrane Database Syst Rev 2006; (1):CD002094.","DOI":"10.1002\/14651858.CD002094.pub4"},{"key":"10.3238\/arztebl.2016.0477_ref101","doi-asserted-by":"crossref","unstructured":"Neumann I, Letelier LM, Rada G, et al.: Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2013; 6: CD007999.","DOI":"10.1002\/14651858.CD007999.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref102","doi-asserted-by":"crossref","unstructured":"Song H, Zhu J, Lu D: Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014; 12: CD010623","DOI":"10.1002\/14651858.CD010623.pub2"},{"key":"10.3238\/arztebl.2016.0477_ref103","unstructured":"Arznei-Telegramm: Seh- und H\u00f6rst\u00f6rungen nach Omeprazol. a-t 1993; 11: 122."},{"key":"10.3238\/arztebl.2016.0477_ref104","unstructured":"Viel hilft viel. Macht das Magenmittel \u201eAntra\u201c, das innere Blutungen stoppt, die Empf\u00e4nger blind und taub? Der Spiegel 1994; 14: 231\u20133."},{"key":"10.3238\/arztebl.2016.0477_ref105","doi-asserted-by":"crossref","unstructured":"Creutzfeldt WC, Blum AL: Safety of omeprazole. Lancet 1994; 343: 1098","DOI":"10.1016\/S0140-6736(94)90207-0"},{"key":"10.3238\/arztebl.2016.0477_ref106","doi-asserted-by":"crossref","unstructured":"Colin-Jones D: Safety of omeprazole and lansoprazole. Lancet 1994; 343: 1369","DOI":"10.1016\/S0140-6736(94)92509-7"},{"key":"10.3238\/arztebl.2016.0477_ref107","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nh\u00f6fer PS: Safety of omeprazole and lansoprazole. Lancet 1994; 343: 1369\u201370","DOI":"10.1016\/S0140-6736(94)92509-7"},{"key":"10.3238\/arztebl.2016.0477_ref108","doi-asserted-by":"crossref","unstructured":"Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al.: Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010; 25: 2205\u201311","DOI":"10.1002\/jbmr.108"},{"key":"10.3238\/arztebl.2016.0477_ref109","doi-asserted-by":"crossref","unstructured":"Hansen KE, Jones AN, Lindstrom MJ, et al.: Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25: 2786\u201395. Erratum in J Bone Miner Res 2011; 26: 439.","DOI":"10.1002\/jbmr.166"},{"key":"10.3238\/arztebl.2016.0477_ref110","doi-asserted-by":"crossref","unstructured":"Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group: The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013; 24: 1161\u20138","DOI":"10.1007\/s00198-012-2112-9"},{"key":"10.3238\/arztebl.2016.0477_ref111","unstructured":"Cai D, Feng W, Jiang Q: Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med 2015; 8: 8893\u2013904"},{"key":"10.3238\/arztebl.2016.0477_ref112","doi-asserted-by":"crossref","unstructured":"Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT: Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344: e372","DOI":"10.1136\/bmj.e372"},{"key":"10.3238\/arztebl.2016.0477_ref113","doi-asserted-by":"crossref","unstructured":"Freedberg DE, Salmasian H, Friedman C, Abrams JA: Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 108: 1794\u2013801","DOI":"10.1038\/ajg.2013.333"},{"key":"10.3238\/arztebl.2016.0477_ref114","doi-asserted-by":"crossref","unstructured":"Freedberg DE, Toussaint NC, Chen SP, et al.: Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015; 149: 883\u20135","DOI":"10.1053\/j.gastro.2015.06.043"},{"key":"10.3238\/arztebl.2016.0477_ref115","doi-asserted-by":"crossref","unstructured":"Lazarus B, Chen Y, Wilson FP, et al.: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176: 238\u201346","DOI":"10.1001\/jamainternmed.2015.7193"},{"key":"10.3238\/arztebl.2016.0477_ref116","doi-asserted-by":"crossref","unstructured":"Gomm W, von Holt K, Thom\u00e9 F, et al.: Association of proton pump inhibitors with risk of dementia: pharmacoepidemiological claims data analysis. JAMA Neurol 2016 [Epub ahead of print].","DOI":"10.1001\/jamaneurol.2015.4791"},{"key":"10.3238\/arztebl.2016.0477_ref117","doi-asserted-by":"crossref","unstructured":"Shah NH, LePendu P, Bauer-Mehren A, et al.: Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015; 10: e0124653.","DOI":"10.1371\/journal.pone.0124653"},{"key":"10.3238\/arztebl.2016.0477_ref118","doi-asserted-by":"crossref","unstructured":"Chan JL, El-Serag HB: Is proton pump inhibitor use associated with risk of myocardial infarction? Gastroenterology 2016; 150: 526\u20138","DOI":"10.1053\/j.gastro.2015.12.016"},{"key":"10.3238\/arztebl.2016.0477_ref119","doi-asserted-by":"crossref","unstructured":"Centanni M, Gargano L, Canettieri G, et al.: Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006; 354: 1787\u201395","DOI":"10.1056\/NEJMoa043903"},{"key":"10.3238\/arztebl.2016.0477_ref120","doi-asserted-by":"crossref","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al.; ACC\/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons: AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: 2354\u201394","DOI":"10.1161\/CIR.0000000000000133"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T12:27:18Z","timestamp":1720268838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":120,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2016.0477","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}